Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02921269 · ClinicalTrials.gov registry record · Phase 2

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

A Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
11
Enrollment target
20
Study locations

NCT02921269: Completed Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by National Cancer Institute (NCI).

NCT02921269 is a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 11 participants, below the 123-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02921269, a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
11 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.

Primary Outcome

Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Complete Response (CR) is the disappearance of all lesions and Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) is CR+PR.

Conditions Studied

Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Recurrent Cervical Carcinoma Cervical Squamous Cell Carcinoma, Not Otherwise Specified Stage IV Cervical Cancer AJCC v6 and v7 Stage IVA Cervical Cancer AJCC v6 and v7 Stage IVB Cervical Cancer AJCC v6 and v7

Interventions

  • DRUG Atezolizumab
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Bevacizumab

Study Locations (20)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

California

  • Los Angeles County-USC Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • Keck Medical Center of USC Pasadena - Pasadena

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital/Winship Cancer Institute - Atlanta

New Jersey

  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital - New Brunswick
  • Rutgers Cancer Institute of New Jersey - New Brunswick

Colorado

  • University of Colorado Hospital - Aurora

Florida

  • Moffitt Cancer Center - Tampa

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2017-03-10
Est. Completion 2021-01-13
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT02921269 record still lists

NCT02921269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 123-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (91% lower).

The record links to 7 conditions, with Cervical Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT02921269 names 20 study sites across 13 states, led by Massachusetts, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT02921269 about?

NCT02921269 is a clinical study titled "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer". This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere ...

What is the current status of trial NCT02921269?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2017-03-10. Estimated completion is 2021-01-13.

What conditions does trial NCT02921269 study?

This clinical trial studies the following conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IV Cervical Cancer AJCC v6 and v7.

What interventions are being tested in trial NCT02921269?

The interventions under investigation include: Atezolizumab (DRUG), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02921269?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02921269 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02921269's enrollment target sits among peer trials

11 14th of 13 the lowest of 13 other Cervical Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cervical Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02921269, the US trial registry maintained by the National Library of Medicine. NCT02921269 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.